Clements CJ, Cutts FT. The epidemiology of measles: thirty years of vaccination. Curr Top Microbiol Immunol.1995;191:13-33.
Cherry JD, Feigin RD, Lobes Jr LA.
et al. Urban measles in the vaccine era: a clinical, epidemiologic, and serologic
study. J Pediatr.1972;81:217-230.
Hardy Jr GE, Kassanoff I, Orbach HG, Case GE, Witte JJ. The failure of a school immunization campaign to terminate an urban
epidemic of measles. Am J Epidemiol.1970;91:286-293.
Black FL. Measles. In: Evans AS, ed. Viral Infections of Humans: Epidemiology
and Control . New York, NY: Plenum Medical Book Co; 1976:297-316.
Babbott Jr FL, Gordon JE. Modern measles. Am J Med Sci.1954;228:334-361.
Aaby P, Clements J, Orinda V. Mortality from measles: measuring the impact. In: World Health Organization, ed. Expanded Programme on Immunization . Geneva, Switzerland:World Health Organization; 1991.
Gindler JS, Atkinson WL, Markowitz LE, Hutchins SS. Epidemiology of measles in the United States in 1989 and 1990. Pediatr Infect Dis J.1992;11:841-846.
Krugman RD, Rosenberg R, McIntosh K.
et al. Further attenuated live measles vaccines: the need for revised recommendations. J Pediatr.1977;91:766-767.
Schluederberg A, Lamm SH, Landrigan PJ, Black FL. Measles immunity in children vaccinated before one year of age. Am J Epidemiol.1973;97:402-409.
Shelton JD, Jacobson JE, Orenstein WA, Schulz KF, Donnell Jr HD. Measles vaccine efficacy: influence of age at vaccination vs. duration
of time since vaccination. Pediatrics.1978;62:961-964.
Shasby DM, Shope TC, Downs H, Herrmann KL, Polkowski J. Epidemic measles in a highly vaccinated population. N Engl J Med.1977;296:585-589.
Wilkins J, Wehrle PF. Additional evidence against measles vaccine administration to infants
less than 12 months of age: altered immune response following active/passive
immunization. J Pediatr.1979;94:865-869.
Yeager AS, Davis JH, Ross LA, Harvey B. Measles immunization: successes and failures. JAMA.1977;237:347-351.
Cherry JD. Measles. In: Feigin R, Cherry J, eds. Textbook of Pediatric Infectious
Diseases . 3rd ed. Philadelphia, Pa: WB Saunders Co; 1992:1591-1609.
Black FL. Measles active and passive immunity in a worldwide perspective. Prog Med Virol.1989;36:1-33.
Lennon JL, Black FL. Maternally derived measles immunity in era of vaccine-protected mothers. J Pediatr.1986;108:671-676.
Markowitz LE, Preblud SR, Fine PE, Orenstein WA. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J.1990;9:101-110.
Pabst HF, Spady DW, Marusyk RG.
et al. Reduced measles immunity in infants in a well-vaccinated population. Pediatr Infect Dis J.1992;11:525-529.
Markowitz LE, Albrecht P, Rhodes P.
et al. for the Kaiser Permanente Measles Vaccine Trial Team. Changing levels of measles antibody titers in women and children in
the United States: impact on response to vaccination. Pediatrics.1996;97:53-58.
Maldonado YA, Lawrence EC, DeHovitz R, Hartzell H, Albrecht P. Early loss of passive measles antibody in infants of mothers with vaccine-induced
Sullender WM, Miller JL, Yasukawa LL.
et al. Humoral and cell-mediated immunity in neonates with herpes simplex
virus infection. J Infect Dis.1987;155:28-37. [published erratum appears in J Infect Dis. 1987;155:838].
Pass RF, Dworsky ME, Whitley RJ, August AM, Stagno S, Alford Jr CA. Specific lymphocyte blastogenic responses in children with cytomegalovirus
and herpes simplex virus infections acquired early in infancy. Infect Immun.1981;34:166-170.
Hayward AR, Herberger MJ, Groothuis J, Levin MR. Specific immunity after congenital or neonatal infection with cytomegalovirus
or herpes simplex virus. J Immunol.1984;133:2469-2473.
Burchett SK, Corey L, Mohan KM, Westall J, Ashley R, Wilson CB. Diminished interferon-gamma and lymphocyte proliferation in neonatal
and postpartum primary herpes simplex virus infection. J Infect Dis.1992;165:813-818.
Hunt DW, Huppertz HI, Jiang HJ, Petty RE. Studies of human cord blood dendritic cells: evidence for functional
Caux C, Massacrier C, Vanbervliet B.
et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med.1994;180:1263-1272.
Brugnoni D, Airo P, Graf D.
et al. Ineffective expression of CD40 ligand on cord blood T cells may contribute
to poor immunoglobulin production in the newborn. Eur J Immunol.1994;24:1919-1924.
Nonoyama S, Penix LA, Edwards CP.
et al. Diminished expression of CD40 ligand by activated neonatal T cells. J Clin Invest.1995;95:66-75.
van Essen D, Kikutani H, Gray D. CD40 ligand-transduced co-stimulation of T cells in the development
of helper function. Nature.1995;378:620-623.
Wedgwood JF, Palmer R, Weinberger B. Development of the ability to make IgG and IgA in newborns and infants. Mt Sinai J Med.1994;61:409-415.
Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism
of measles vaccine failure. J Pediatr.1977;91:715-718.
Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization
test. J Virol Methods.1981;3:251-260.
Ratnam S, Gadag V, West R.
et al. Comparison of commercial enzyme immunoassay kits with plaque reduction
neutralization test for detection of measles virus antibody. J Clin Microbiol.1995;33:811-815.
Chen RT, Markowitz LE, Albrecht P.
et al. Measles antibody: reevaluation of protective titers. J Infect Dis.1990;162:1036-1042.
Johnson CE, Nalin DR, Chui LW, Whitwell J, Marusyk RG, Kumar ML. Measles vaccine immunogenicity in 6- versus 15-month-old infants born
to mothers in the measles vaccine era. Pediatrics.1994;93:939-944.
Not Available. Measles outbreak—southwestern Utah, 1996. MMWR Morb Mortal Wkly Rep.1997;46:766-769.
Atkinson WL, Hadler SC, Redd SB, Orenstein WA. Measles surveillance—United States, 1991. MMWR CDC Surveill Summ.1992;41:1-12.
American Academy of Pediatrics. Measles. In: Peter G, ed. 1997 Red Book: Report of the Committee on
Infectious Diseases . 24th ed. Elk Grove Village, Ill: American Academy
of Pediatrics; 1997:344-357.
Martinez X, Brandt C, Saddallah F.
et al. DNA immunization circumvents deficient induction of T helper type 1
and cytotoxic T lymphocyte responses in neonates and during early life. Proc Natl Acad Sci U S A.1997;94:8726-8731.
Ward BJ, Boulianne N, Ratnam S, Guiot MC, Couillard M, De Serres G. Cellular immunity in measles vaccine failure: demonstration of measles
antigen-specific lymphoproliferative responses despite limited serum antibody
production after revaccination. J Infect Dis.1995;172:1591-1595.
Markowitz L, Katz S. Measles vaccine. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines . 2nd ed.
Philadelphia, Pa: WB Saunders Co; 1994:229-276.
Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: an hypothesis for altered
immune responses. J Infect Dis.1994;170(suppl 1):S24-S31.
Karp CL, Wysocka M, Wahl LM.
et al. Mechanism of suppression of cell-mediated immunity by measles virus. Science.1996;273:228-231.
Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the
priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med.1996;183:693-698.
Schmitt E, Hoehn P, Huels C.
et al. T helper type 1 development of naive CD4+ T cells requires the coordinate
action of interleukin-12 and interferon-gamma and is inhibited by transforming
growth factor-beta. Eur J Immunol.1994;24:793-798.
Kennedy MK, Picha KS, Fanslow WC.
et al. CD40/CD40 ligand interactions are required for T cell-dependent production
of interleukin-12 by mouse macrophages. Eur J Immunol.1996;26:370-378.
Ward BJ, Griffin DE. Changes in cytokine production after measles virus vaccination: predominant
production of IL-4 suggests induction of a Th2 response. Clin Immunol Immunopathol.1993;67:171-177.
Griffin DE. Immune responses during measles virus infection. Curr Top Microbiol Immunol.1995;191:117-134.
Griffin DE, Ward BJ. Differential CD4 T cell activation in measles. J Infect Dis.1993;168:275-281.
Hussey GD, Goddard EA, Hughes J.
et al. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune
response in infants. J Infect Dis.1996;173:1320-1326.
Oxenius A, Campbell KA, Maliszewski CR.
et al. CD40-CD40 ligand interactions are critical in T-B cooperation but not
for other anti-viral CD4+ T cell functions. J Exp Med.1996;183:2209-2218.
Klaus SJ, Berberich I, Shu G, Clark EA. CD40 and its ligand in the regulation of humoral immunity. Semin Immunol.1994;6:279-286.
Siegrist CA. Potential advantages and risks of nucleic acid vaccines for infant
Linnemann Jr CC, Dine MS, Roselle GA, Askey PA. Measles immunity after revaccination: results in children vaccinated
before 10 months of age. Pediatrics.1982;69:332-335.
Cutts FT, Nyandu B, Markowitz LE.
et al. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in
3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine
in 6-month-old infants, in Kinshasa, Zaire. Vaccine.1994;12:1311-1316.
McGraw TT. Reimmunization following early immunization with measles vaccine: a
prospective study. Pediatrics.1986;77:45-48.
Murphy MD, Brunell PA, Lievens AW, Shehab ZM. Effect of early immunization on antibody response to reimmunization
with measles vaccine as demonstrated by enzyme-linked immunosorbent assay
Stetler HC, Orenstein WA, Bernier RH.
et al. Impact of revaccinating children who initially received measles vaccine
before 10 months of age. Pediatrics.1986;77:471-476.